Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Patients with β-thalassemia show 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection, representing a high-risk population compared with age- and sex-matched healthy subjects. Vaccination against SARS-CoV-2 is crucial to reduce mortality and morbidity of frail patients. Up to now, limited data have been available on the responses of patients with β-thalassemia immunized with anti-SARS-CoV-2 mRNA vaccines.

The main aim of the present prospective multicenter study was to evaluate the immunogenicity of the SARS-CoV-2 mRNA vaccine BNT162b2 in patients with transfusion-dependent β-thalassemia (TDT). Patients with TDT (n = 154), vaccinated within the Nationwide Vaccination Program in Italy, were enrolled in 7 comprehensive Italian centers for hemoglobinopathies. Serum samples were collected before vaccination (T0), 2 weeks after the second dose (T1), 12 weeks after the second dose (T2), before the third dose (T3), and at 4 and 12 weeks after the third dose (respectively, T4 and T5) (supplemental Figure 1A, available on the Blood website). A group of healthcare workers (HCWs) enrolled at INMI L. Spallanzani served as control group. Previous and breakthrough SARS-CoV-2 infections were diagnosed by a reverse transcriptase polymerase chain reaction test or seroconversion to antinucleocapsid antibodies. The response to vaccination was evaluated by quantifying anti-RBD antibodies (Abbott Laboratories, Wiesbaden, Germany). The spike protein–specific T-cell response was evaluated in a subset of patients (n = 12) by an interferon-γ-releasing assay performed on whole blood. In the same group of patients, spike protein–specific memory B cells were detected and quantified by flow cytometry or ELISpot. The study was approved by the Comitato Etico dell’Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS as the National Review Committee Board for the COVID-19 pandemic in Italy, and registered with clinicaltrials.gov (NCT05157256).

Overall, 154 patients with TDT and 82 HCWs were enrolled in this study; all subjects received the mRNA BNT162b2 vaccine. Demographic and clinical patients’ characteristics are summarized in Table 1. After vaccinations, no serious adverse events related to vaccination were reported in the study population. Moreover, no COVID-related hospitalization or death was recorded in the study population.

As shown in Figure 1A, after 2 doses (T1), infection-naïve patients TDT (n = 132) showed an optimal rate of seroconversion to anti-RBD IgG (131/132, 99.2%), similarly to the control HCWs (82/82, 100%). The anti-RBD titers of infection-naïve TDT and HCW subjects were similar at T1, thus confirming excellent response to the vaccine. At T2, however, 12 weeks after the second dose, anti-RBD antibodies were significantly lower in patients with TDT than in controls (estimated difference, 26.6 BAU/mL; confidence interval, 55-244 BAU/mL). At T3, just before the third dose, anti-RBD antibodies were lower in patients with TDT than in controls without reaching statistically significant difference (P = .056; estimated difference, 26.6 BAU/mL; confidence interval, −0.7 to 55 BAU/mL). Thus, notwithstanding the optimal response to the vaccine, antibody titers declined more rapidly in patients with TDT than in HCWs after the first 2 doses. Similar kinetics was observed for the spike protein–specific T- and B-cell responses (Figure 1B; supplemental Figure 1B), confirming a good immune response early after vaccination that decreases faster over time in patients with TDT than in age-matched HCWs. The third dose was able to
improve the immune response of patients with TDT (T4 vs T3, \( P < .0001 \)), reaching 100% seropositivity rate, with a similar anti-RBD titer in the TDT and HCW groups (T4) (Figure 1B). Of note, the level of anti-RBD antibodies was higher at T4, 4 weeks after the third dose, than at T1 (T1: \( R_p = -0.16; P = .068 \)), reaching statistical significance at T2, corresponding to 12 weeks after the second vaccine dose (T2: \( R_p = -0.21; P = .019 \)). This correlation was lost at later time points and after the third vaccination. The behavior of anti-RBD antibody response to BNT162b2 vaccination in patients with TDT was similar to that reported in healthy subjects over 80 years of age,\(^5,8\) for whom the effect of age disappears after the third dose and further ones.\(^7\) Of note, evidence of premature aging of the immune system has been reported in patients with TDT.\(^7-10\) This might be related to different factors, including multiple transfusions as alloantigen stimulation associated or iron overload, negatively affecting Th response. Indeed, TDT patients have been shown to have (1) reduced CD4/CD8 ratio, (2) increased circulating interleukin (IL-17) and transforming growth factor \( \beta \) with possible detrimental effect on T-cell immune response, and (3) reduction in IL-2 and interferon-\( \gamma \) production by activated lymphocytes from patients with TDT compared with healthy control subjects.\(^12-14\) A similar immunosenescent profile has also been invoked for the inverse relationship between neutralizing response and age in healthy elderly subjects, who are characterized by restriction of T- and B-cell repertoires\(^15,16\) and by general defects in CD4 and CD8 T-cell activation, differentiation, and function (proliferation and cytokines production), hindering a protective long-lasting immune response.\(^17\) Further analysis focusing on the expression of inhibitory/senescent markers on T cells could help in clarifying their role in dampening the strength as well as the persistence of vaccine-induced immunity both in naive and in previously SARS-CoV-2–infected patients with TDT.

In conclusion, our data seem to indicate that immune response of patients with TDT to SARS-CoV-2 vaccination is similar to that reported in healthy elderly subjects, suggesting a premature aging of the immune system of patients with TDT. Our results demonstrate the relevance of a third dose of mRNA vaccine for patients with TDT, who represent a population at high risk of developing severe complications and fatal events related to SARS-CoV-2 infection. Antibodies, produced immediately after vaccination, are the product of short-lived plasmablasts, whereas maintenance of antibody concentrations over time depends on the function and number of long-lived plasma cells.\(^18\) The third vaccine dose is therefore needed to increase the number of long-lived plasma cells in patients with TDT, thus ensuring more effective protection, as shown for the elderly. It remains to be fully elucidated whether the third vaccine dose also improves the maintenance of memory T- and B-cell responses over time.

We then assessed the possible impact of clinical variables on the humoral response. We first compared anti-RBD antibodies by age, sex, splenectomy, and chelation therapy. We found no evidence for any association at each time point except for age (Figure 1C; supplemental Figure 2). As shown in Figure 1C, we observed a slight negative correlation (Pearson correlation coefficient, \( R_p \)) between age and anti-RBD titer at T1 (T1: \( R_p = -0.16; P = .068 \)), reaching statistical significance at T2, corresponding to 12 weeks after the second vaccine dose (T2: \( R_p = -0.21; P = .019 \)). This correlation was lost at later time points and after the third vaccination. The behavior of anti-RBD antibody response to BNT162b2 vaccination in patients with TDT was similar to that reported in healthy subjects over 80 years of age,\(^5,8\) for whom the effect of age disappears after the third dose and further ones.\(^7\) Of note, evidence of premature aging of the immune system has been reported in patients with TDT.\(^7-10\) This might be related to different factors, including multiple transfusions as alloantigen stimulation associated or iron overload, negatively affecting Th response. Indeed, TDT patients have been shown to have (1) reduced CD4/CD8 ratio, (2) increased circulating interleukin (IL-17) and transforming growth factor \( \beta \) with possible detrimental effect on T-cell immune response, and (3) reduction in IL-2 and interferon-\( \gamma \) production by activated lymphocytes from patients with TDT compared with healthy control subjects.\(^12-14\) A similar immunosenescent profile has also been invoked for the inverse relationship between neutralizing response and age in healthy elderly subjects, who are characterized by restriction of T- and B-cell repertoires\(^15,16\) and by general defects in CD4 and CD8 T-cell activation, differentiation, and function (proliferation and cytokines production), hindering a protective long-lasting immune response.\(^17\) Further analysis focusing on the expression of inhibitory/senescent markers on T cells could help in clarifying their role in dampening the strength as well as the persistence of vaccine-induced immunity both in naive and in previously SARS-CoV-2–infected patients with TDT.

In conclusion, our data seem to indicate that immune response of patients with TDT to SARS-CoV-2 vaccination is similar to that reported in healthy elderly subjects, suggesting a premature aging of the immune system of patients with TDT. Our results demonstrate the relevance of a third dose of mRNA vaccine for patients with TDT, who represent a population at high risk of developing severe complications and fatal events related to SARS-CoV-2 infection. Antibodies, produced immediately after vaccination, are the product of short-lived plasmablasts, whereas maintenance of antibody concentrations over time depends on the function and number of long-lived plasma cells.\(^18\) The third vaccine dose is therefore needed to increase the number of long-lived plasma cells in patients with TDT, thus ensuring more effective protection, as shown for the elderly. It remains to be fully elucidated whether the third vaccine dose also improves the maintenance of memory T- and B-cell responses over time.

---

**Table 1. Main characteristics of subjects included in the analysis**

| Subjects’ characteristics | Value * |
|---------------------------|--------|
| **HCWs**                  |        |
| Men                       | 21 (25.6%) |
| Women                     | 61 (74.4%) |
| Age, y                    | 45.0 (35.0-53.0) |
| **SARS-CoV-2**            |        |
| Naive                     | 82 (100%) |
| Previously infected       |        |
| **TDT patients**          |        |
| Men                       | 61 (39.6%) |
| Women                     | 93 (60.4%) |
| Age, y                    | 44.0 (37.0-51.0) |
| Splenectomized            | 83 (53.9%) |
| **ICT**                   |        |
| DFX                       | 154    |
| DFP                       | 80 (51.9%) |
| DFO                       | 20 (13.0%) |
| Combined                  | 18 (11.7%) |
| Not available             | 31 (20.1%) |
| HU                        | 5 (3.2%) |
| **SARS-CoV-2**            |        |
| Naive                     | 132 (85.7%) |
| Previously infected       | 22 (14.3%) |

**Table 1. Main characteristics of subjects included in the analysis**

*Values are n, n (%), or median (interquartile range). DFO, deferasirox; DFP, deferasprone; DFX, deferascum; HCWs, healthcare workers; HU, hydroxyurea; ICT, iron chelation therapy; TDT, transfusion-dependent \( \beta \)-thalassemia.*
Acknowledgments

The authors thank the ForAnemia Foundation (Genova, Italy) for methodologic support, the Associazione per la Lotta alla Talassemia R. Vullo (Ferrara, Italy), and Giulia Albasini for logistical support.

The study was supported by the Italian Ministry of Health (Ricerca Corrente to INMI, Linea 1).

Authorship

Contribution: G.L.F. and F.L. designed the research; R.G., M. Fortini, S.B., R.D., S.P., M. Casale, A.M., L.F., E.T., M. Caminati, F.M., and L.D.F. managed the patients; C.A., R.C., E.T., E.P.M., F.C., V.P., M. Francalancia, and V.M. performed research; R.C., C.A., and B.G. analyzed and interpreted data; B.G. performed statistical analysis; C.A., R.C., V.M.P., G.L.F., F.L., and L.D.F. wrote the manuscript; and all authors approved the final version of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation for C.A. is Department of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy.

ORCID profiles: R.C., 0000-0002-2632-1078; V.M.P., 0000-0002-8375-6289; M. Fortini, 0000-0001-8406-0024; S.P., 0000-0001-6149-6845; E.T., 0000-0001-5773-7781; E.P.M., 0000-0002-0054-4732; M. Francalancia, 0000-0003-3133-9237; M. Caminati, 0000-0001-7383-1487; L.D.F., 0000-0001-7093-777X; G.L.F., 0000-0001-9833-1016.

Correspondence: Gian Luca Forni, Centro della Microcitemia e delle Anemie, Congenite, Ospedale Galliera, Via Volta 6, Genova 16128, Italy; email: gianluca.forni@galliera.it.

Footnotes

Submitted 30 June 2022; accepted 11 August 2022; prepublished online on Blood First Edition 24 August 2022.

*R.C. and C.A. contributed equally to this work as first authors.

Data will be available on demand.

The online version of this article contains a data supplement.

REFERENCES

1. Longo F, Gianesin B, Voi V, et al. Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection. Am J Hematol. 2022;97(2):E75-E78.

2. Oosting SF, van der Veldt AAM, Fehrmann RSN, et al. Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. Lancet Oncol. 2022;23(7):833-835.
3. Delaporta P, Terpos E, Solomou EE, et al. Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemia. Br J Haematol. 2022;197(5):576-579.

4. Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol. 2022;7(68): eabn8014.

5. Wheeler SE, Shurin GV, Yost M, et al. Differential antibody response to mRNA COVID-19 vaccines in healthy subjects. Microbiol Spectr. 2021;9(1): e0034121.

6. Schwartz T, Tober-Lau P, Hillius D, et al. Delayed antibody and T-cell response to BNT162b2 vaccination in the elderly. Emerg Infect Dis. 2021;27(8):2174-2178.

7. Zhang J, Xing S, Liang D, et al. Differential antibody response to inactivated COVID-19 vaccines in healthy subjects. Front Cell Infect Microbiol. 2021;11:791660.

8. Collier DA, Ferreira IATM, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596(7872):417-422.

9. Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A. Pathogenetic aspects of immune deficiency associated with beta-thalassaemia. Med Sci Monit. 2003;9(1):RA19-RA22.

10. Sternbach MS, Tsoukas C, Paquin M, Lajeunesse N, Strawczynski H. Dependent platelet activation and to activate granulocytes to release procoagulant neutrophil extracellular traps. 6,8 Serum anti-PF4 antibodies are mostly transient and appear in serum within days of vaccination, suggesting a recall immune response on memory B cells. 9

TO THE EDITOR:

Vaccine-induced immune thrombotic thrombocytopenia is mediated by a stereotyped clonotypic antibody

Jing Jing Wang,1,2 Bridie Armour,1,2 Tim Chataway,3 Alexander Troelnikov,1,2 Alex Colella,3 Olivia Yacoub,4 Simon Hockley,5 Chee Wee Tan,4,6 and Tom Paul Gordon1,2

1Department of Immunology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia; 2Department of Immunology, South Australia (SA) Pathology (Flinders Medical Centre), Bedford Park, SA, Australia; 3Flinders Proteomics Facility, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia; 4SA Pathology, Adelaide, SA, Australia; 5Intensive Care Unit, Calvary Hospital, Adelaide, SA, Australia; and 6Department of Haematology, Royal Adelaide Hospital, Central Area Local Health Network (CALHN), Adelaide, SA, Australia

The syndrome of vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare thromboembolic complication of adenoviral-vectored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.Cov2.S (Janssen/Johnson & Johnson) mediated by antibodies directed against platelet factor 4 (PF4).1-5 The mechanisms by which the adenoviral DNA vectors break immune tolerance to PF4 and trigger B-cell clonal expansion and secretion of anti-PF4 immunoglobulin Gs (IgGs) are under intense investigation and likely involve formation of immunogenic complexes of PF4 with vaccine components in a proinflammatory setting.6-8 Pathogenic anti-PF4 IgGs subsequently form circulating immune complexes with PF4 tetramers, which are thought to drive thrombotic events by Fc γ receptor IIa-dependent platelet activation and to activate granulocytes to release procoagulant neutrophil extracellular traps.6,8 Serum anti-PF4 antibodies are mostly transient and appear in serum within days of vaccination, suggesting a recall immune response on memory B cells.9

Given their causal role in VITT, identification of the molecular composition of the anti-PF4 antibodies and their antigenic target(s) is crucial for better understanding of the pathogenesis and for developing better diagnostics and treatments. In a key advance, Huynh et al have mapped the antibody-binding site to a single conformational epitope on the PF4 molecule, which is located within the heparin-binding site and distinct from epitopes bound by serum from patients with heparin-induced thrombocytopenia (HIT).10 Moreover, a recent intact mass spectrometric analysis of anti-PF4 IgGs in patients with VITT and HIT revealed...